Roth Capital Issues Pessimistic Forecast for TLSI Earnings

TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Free Report) - Equities research analysts at Roth Capital decreased their Q2 2025 earnings estimates for shares of TriSalus Life Sciences in a research note issued on Wednesday, May 21st. Roth Capital analyst J. Wittes now forecasts that the company will post earnings of ($0.19) per share for the quarter, down from their previous estimate of ($0.11). The consensus estimate for TriSalus Life Sciences' current full-year earnings is ($1.55) per share. Roth Capital also issued estimates for TriSalus Life Sciences' Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.72) EPS and FY2026 earnings at ($0.29) EPS.

Several other research firms also recently commented on TLSI. Roth Mkm reaffirmed a "buy" rating and issued a $11.00 price objective on shares of TriSalus Life Sciences in a report on Friday, January 24th. Lake Street Capital assumed coverage on shares of TriSalus Life Sciences in a report on Thursday, February 13th. They issued a "buy" rating and a $10.00 price objective on the stock. Finally, Canaccord Genuity Group reissued a "buy" rating and set a $11.00 price target on shares of TriSalus Life Sciences in a report on Friday, March 28th. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, TriSalus Life Sciences currently has an average rating of "Buy" and a consensus target price of $10.93.

TriSalus Life Sciences Price Performance

TLSI stock opened at $5.35 on Friday. The firm's fifty day simple moving average is $5.41 and its 200-day simple moving average is $5.03. The company has a market capitalization of $172.66 million, a P/E ratio of -2.15 and a beta of 0.50. TriSalus Life Sciences has a 12 month low of $3.50 and a 12 month high of $9.85.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.13). The firm had revenue of $9.17 million for the quarter, compared to analyst estimates of $9.04 million. During the same quarter in the prior year, the business earned ($0.60) earnings per share.

Hedge Funds Weigh In On TriSalus Life Sciences

Large investors have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. acquired a new position in TriSalus Life Sciences during the first quarter worth $55,000. Renaissance Technologies LLC purchased a new position in shares of TriSalus Life Sciences in the fourth quarter worth about $67,000. Connective Capital Management LLC purchased a new position in shares of TriSalus Life Sciences in the fourth quarter worth about $140,000. Northern Trust Corp lifted its stake in shares of TriSalus Life Sciences by 22.7% in the fourth quarter. Northern Trust Corp now owns 32,112 shares of the company's stock worth $161,000 after buying an additional 5,936 shares in the last quarter. Finally, Goldman Sachs Group Inc. purchased a new position in shares of TriSalus Life Sciences in the first quarter worth about $187,000. 2.58% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other TriSalus Life Sciences news, insider Richard Marshak sold 6,597 shares of the company's stock in a transaction on Monday, May 19th. The shares were sold at an average price of $5.18, for a total transaction of $34,172.46. Following the completion of the transaction, the insider now directly owns 69,101 shares in the company, valued at approximately $357,943.18. This represents a 8.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last three months, insiders have sold 16,125 shares of company stock valued at $83,528. Corporate insiders own 27.50% of the company's stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.